R&D News | pharmaphorum

News

Trial of 2seventy bio’s AML cell therapy paused after fatali...

Shares in 2seventy bio were on the slide this morning after the US biotech said Seattle Children’s Therapeutics had paused a clinical trial of its T-cell therapy for acute

News

Kura files $100m offer after menin inhibitor results in AML...

The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog

News

Seagen says Adcetris/Opdivo combo aces lymphoma trial

Seagen’s Adcetris was trounced by Bristol-Myers Squibb’s Opdivo in a head-to-head trial in classical Hodgkin lymphoma (cHL) reported at ASCO – but there may be a way for t

News

Valneva preps for FDA verdict on chikungunya vaccine

With an FDA decision in its marketing application for chikungunya vaccine VLA1553 just a couple of months away, Valneva has published data reinforcing the clinical evidenc

News

Almirall eyes pipeline expansion with €200m funding

Spanish pharma Almirall has closed a €200 million share capital raise that will be used in part to close pipeline-boosting activities – including bolt-on acquisitions and

News

UK must not overlook manufacturing in life sciences drive

To meet its aspiration of becoming a life sciences superpower, the UK must not only discover and develop new medicines – it must also be able to manufacture them at scale,

Trial of 2seventy bio’s AML cell therapy paused after fatali...

Kura files $100m offer after menin inhibitor results in AML...

Seagen says Adcetris/Opdivo combo aces lymphoma trial

Valneva preps for FDA verdict on chikungunya vaccine

Almirall eyes pipeline expansion with €200m funding

UK must not overlook manufacturing in life sciences drive

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks